Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 2 - What They Never Told You

8 Oral Cancer Warning Symptoms Indian Men Keep Ignoring, From Lesions to Screening Delays

A White Patch That Will Not Go AwayLeukoplakia, a thick white or greyish patch inside the mouth, is one of the most documented precancerous lesions in Indian men who use smokeless tobacco. A 2020 study published in the Indian Journal of Cancer found that leukoplakia was present in nearly 60%…

Times Life

Myeloma's Most Effective New Drugs Require a Hospital Stay to Start, and That Is Keeping Them Out of Reach for Rural Patients

Bispecific antibodies work in advanced myeloma, but startup requirements keep them at academic centers. New guidance aims to close the community gap.

Medical Daily

FDA Renamed and Updated Its Companion Diagnostics List, Including the First Test That Detects Cancer's Return in Blood

FDA updated its companion diagnostics list on July 23, adding tests that decide who gets targeted cancer drugs, including a blood-based MRD test.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions…

The Economic Times

FDA Approves Revtorpyk for a Breast Cancer Subgroup That Had Been Left Out of Targeted Treatment

FDA approved Revtorpyk (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer. VIKTORIA-1 showed 9.3 months of PFS versus 2.0.

Medical Daily

Scientists Apply Evolution Theory to Cancer Treatment, and Timed Drug Switching Could Beat Resistance

A Genetics study published July 22, 2026, uses evolutionary biology math models to show that timed drug switching before tumor recovery could beat cancer resistance. Here is what the approach means.

Medical Daily

FDA Expands Keytruda Approval to All Bladder Cancer Patients Before Surgery, Not Just Those Avoiding Chemo

The FDA expanded Keytruda plus Padcev to all muscle-invasive bladder cancer patients on July 10, 2026. Here is who now qualifies and what the KEYNOTE-B15 trial showed.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

FDA Approves First Drug Specifically for 60 Percent of Metastatic Breast Cancer Patients Who Had No Prior Options

The FDA approved gedatolisib (Revtorpyk) on July 14, 2026, for HR+/HER2- advanced breast cancer patients without a PIK3CA mutation. Here is who qualifies and what the trial showed.

Medical Daily

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company…

The Economic Times

Treating Cancer Like an Evolving Ecosystem Could Beat Drug Resistance, New Mathematical Models Suggest

New mathematical models in Genetics published July 22 show that timed therapy switching before tumor regrowth could outperform maximum-dose cancer treatment by exploiting resistance evolution.

Medical Daily

Six Cancer Drug Approvals in One Quarter: What the FDA Cleared in Q2 2026 and Who It Helps

FDA approved 6 cancer drugs in Q2 2026, covering breast, prostate, kidney, bladder, and blood cancers. Here's what was approved, who qualifies, and what it means.

Medical Daily

A Breast Cancer Drug Decision Due July 17 Could Open a New Treatment Path for 37,000 Women a Year Who Have No Good Options Now

FDA decides on gedatolisib July 17, 2026, for HR+/HER2-/PIK3CA wild-type advanced breast cancer. A Phase 3 trial showed 76% risk reduction in progression. 37,000 patients per year.

Medical Daily

Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread

In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere – from NPR and The Washington Post to Substack and heated exchanges on social media – all circling the same…

The Conversation

GLP-1 Drugs Are Now Being Tested Alongside Chemotherapy in Cancer Patients

A University of Arizona trial is testing GLP-1 drugs with chemotherapy in metastatic pancreatic, colorectal, and liver cancer patients. Here's what the study asks.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer...

AAP

Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific

DA NANG, Vietnam, June 18, 2026 /PRNewswire/ -- Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought together leading oncology experts, clinicians, researchers and healthcare stakeholders to discuss how Artificial Intelligence (AI) and multi-omics are reshaping cancer care across Asia-Pacific.Held in Da Nang,…

The Economic Times

Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.

Medical Daily

Personalized mRNA Cancer Vaccine Shows Five-Year Data Stunning Oncologists with 69 Percent of Stage III IV Melanoma Patients Cancer-Free

ASCO 2026 (June 3, 2026) and Journal of Clinical Oncology: Intismeran autogene + Keytruda shows 49% sustained recurrence reduction at 5 years, 59% distant metastasis reduction, and 53% overall survival benefit in high-risk Stage III/IV melanoma. 69% of combination patients are cancer-free at 5 years.

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

FLORENCE, Italy and NEW YORK, June 14, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal…

MarketBeat

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

The Economic Times

Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform global

Precision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform, OncoTwin. The company aims to make precision oncology inclusive for under-represented populations. 4baseCare is also decentralising genomic testing infrastructure in India. This move brings advanced cancer diagnostics closer…

MarketBeat

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York. Kuan said the company believes the therapy cou

MarketBeat

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

MarketBeat

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company

MarketBeat

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.